차세대 시퀀싱 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2025-2034년)

Growth Factors of next-generation sequencing (NGS) Market

The global next-generation sequencing (NGS) market was valued at USD 10.44 billion in 2025 and is projected to reach USD 11.79 billion in 2026, eventually growing to USD 38.34 billion by 2034, representing a CAGR of 15.88% during the forecast period. North America dominated the market in 2025 with a 56.01% share, driven by advanced research infrastructure, significant R&D investments, strong adoption of genomics in clinical and research applications, and the presence of leading players like Illumina Inc., Thermo Fisher Scientific Inc., and PacBio.

Next-generation sequencing is a revolutionary technology that enables high-throughput, scalable, and rapid DNA sequencing, transforming genomics research and clinical diagnostics. Its applications span genetic testing, non-invasive prenatal testing, oncology, infectious disease monitoring, and personalized medicine. The COVID-19 pandemic accelerated NGS adoption as the technology was used to study, monitor, and sequence the SARS-CoV-2 virus, boosting research activities and investments in vaccine development.

Key Market Drivers

Diversified Applications in Diagnostics and Research: The decreasing costs of NGS and its high accuracy have expanded its applications in diagnostics, including cancer screening, reproductive health, genetic disorder detection, and companion diagnostics. For example, Thermo Fisher Scientific and Bayer collaborated in March 2024 to develop NGS-based companion diagnostic assays, supporting clinical pipelines.

Technological Advancements and Product Innovation: Continuous innovation in instruments and consumables has enhanced sequencing speed, accuracy, and data analysis. In June 2022, PerkinElmer launched the BioQule NGS System, an automated benchtop solution, while Illumina introduced Connected Insights, a cloud-based software for clinical NGS data analysis in March 2023. These advancements increase accessibility, efficiency, and adoption across research and clinical applications.

Government Initiatives and Genome Projects: Large-scale genome projects, such as the Genome India Project, Personalized Medicine Program (France), and Saudi Human Genome Program, have accelerated NGS adoption. Governments globally are funding genomic research to enhance disease diagnosis, personalized medicine, and biotechnology development.

Market Restraints

The growth of the NGS market faces challenges such as shortage of skilled personnel in developing nations, high investment requirements, and data storage limitations due to the massive volume of sequencing data generated. Additionally, emerging regions may lack sufficient infrastructure to fully leverage NGS technologies, restraining adoption.

Market Segmentation

By Type: The market is segmented into products and services. The products segment dominated the market in 2026 with 86.10% share, including instruments and consumables, due to high usage volume, continuous product launches, and availability. Services, including sequencing as a service, are projected to grow steadily as outsourcing increases.

By Technology: Sequencing technologies include Sequencing by Synthesis (SBS), nanopore sequencing, Ion semiconductor sequencing, and others. SBS held 68.41% share in 2026, led by Illumina's strong product portfolio. Nanopore sequencing is projected to grow rapidly due to portability and long-read capabilities.

By Application: The market is segmented into clinical and research & applied. Clinical applications dominated in 2026 with 51.96% share, driven by oncology, cardiovascular, genetic disorder diagnostics, and reproductive health. Research applications are expected to grow due to large-scale projects and technological adoption.

By End-User: Pharmaceutical & biotechnology companies accounted for 48.00% share in 2026, driven by research collaborations, drug discovery, and NGS adoption in development pipelines. Academic and research institutes are also increasing adoption due to government research funding and genome projects.

Regional Insights

North America generated USD 5.85 billion in 2025 and is projected to reach USD 6.18 billion by 2026, maintaining dominance due to strong research funding and advanced infrastructure. Asia Pacific is expected to witness the highest CAGR, driven by initiatives like the Genome India Project and rapid adoption of genomic medicine in China and Japan. Europe benefits from strong healthcare infrastructure and government support for genomics research. Latin America and the Middle East & Africa are projected to witness moderate growth, supported by partnerships and capacity expansion in genomics.

Competitive Landscape

The NGS market is highly consolidated, led by Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., QIAGEN, PacBio, Oxford Nanopore Technologies, PerkinElmer, and BGI. Key strategies include product innovation, collaborations, capacity expansion, and strategic partnerships. For instance, Illumina and HaploX collaborated in 2023 to provide locally manufactured sequencing instruments in China.

Conclusion

The global NGS market is projected to experience substantial growth from 2025 to 2034, driven by declining sequencing costs, expanded clinical and research applications, genome projects, technological innovation, and government support. North America remains the largest market, while Asia Pacific is expected to grow at the fastest rate. Dominance in products, SBS technology, clinical applications, and pharmaceutical & biotechnology end-users is expected to continue. Strategic initiatives by major players, along with advancements in sequencing platforms, will drive the market to reach USD 38.34 billion by 2034, enabling improved genomic research, diagnostics, and personalized healthcare worldwide.

Segmentation By Type

• Products
  • Instruments
  • Consumables
• Services

By Technology

• Sequencing By Synthesis (SBS)
• Nanopore Sequencing
• ION Semiconductor Sequencing
• Others

By Application

• Research & Applied
• Clinical
  • Cardiovascular
  • Oncology
  • Genetic Diseases
  • Reproductive Health

By End-User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Region

• North America (By Type, Technology, Application, End-User, and Country)
  • U.S.
  • Canada
• Europe (By Type, Technology, Application, End-User, and Country/ Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Technology, Application, End-User, and Country/ Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Latin America (By Type, Technology, Application, End-User, and Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Technology, Application, End-User, and Country/ Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries, 2025
• 4.2. Overview: Regulatory Scenario & Reimbursement Scenario, By Key Countries/Region
• 4.3. New Product Launches, By Key Players
• 4.4. Key Industry Developments, By Key Players
• 4.5. Overview: Technological Advancements in Next-generation Sequencing
• 4.6. Impact of COVID-19 on the Market

5. Global Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Products
    • 5.1.1.1. Instruments
    • 5.1.1.2. Consumables
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Sequencing By Synthesis (SBS)
  • 5.2.2. Nanopore Sequencing
  • 5.2.3. ION Semiconductor Sequencing
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Research & Applied
  • 5.3.2. Clinical
    • 5.3.2.1. Cardiovascular
    • 5.3.2.2. Oncology
    • 5.3.2.3. Genetic Diseases
    • 5.3.2.4. Reproductive Health
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. Academic & Research Institutes
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Products
    • 6.1.1.1. Instruments
    • 6.1.1.2. Consumables
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Sequencing By Synthesis (SBS)
  • 6.2.2. Nanopore Sequencing
  • 6.2.3. ION Semiconductor Sequencing
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Research & Applied
  • 6.3.2. Clinical
    • 6.3.2.1. Cardiovascular
    • 6.3.2.2. Oncology
    • 6.3.2.3. Genetic Diseases
    • 6.3.2.4. Reproductive Health
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. Academic & Research Institutes
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Products
    • 7.1.1.1. Instruments
    • 7.1.1.2. Consumables
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Sequencing By Synthesis (SBS)
  • 7.2.2. Nanopore Sequencing
  • 7.2.3. ION Semiconductor Sequencing
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Research & Applied
  • 7.3.2. Clinical
    • 7.3.2.1. Cardiovascular
    • 7.3.2.2. Oncology
    • 7.3.2.3. Genetic Diseases
    • 7.3.2.4. Reproductive Health
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. Academic & Research Institutes
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Products
    • 8.1.1.1. Instruments
    • 8.1.1.2. Consumables
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Sequencing By Synthesis (SBS)
  • 8.2.2. Nanopore Sequencing
  • 8.2.3. ION Semiconductor Sequencing
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Research & Applied
  • 8.3.2. Clinical
    • 8.3.2.1. Cardiovascular
    • 8.3.2.2. Oncology
    • 8.3.2.3. Genetic Diseases
    • 8.3.2.4. Reproductive Health
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. Academic & Research Institutes
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Products
    • 9.1.1.1. Instruments
    • 9.1.1.2. Consumables
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Sequencing By Synthesis (SBS)
  • 9.2.2. Nanopore Sequencing
  • 9.2.3. ION Semiconductor Sequencing
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Research & Applied
  • 9.3.2. Clinical
    • 9.3.2.1. Cardiovascular
    • 9.3.2.2. Oncology
    • 9.3.2.3. Genetic Diseases
    • 9.3.2.4. Reproductive Health
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. Academic & Research Institutes
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Next-generation Sequencing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Products
    • 10.1.1.1. Instruments
    • 10.1.1.2. Consumables
  • 10.1.2. Services
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. Sequencing By Synthesis (SBS)
  • 10.2.2. Nanopore Sequencing
  • 10.2.3. ION Semiconductor Sequencing
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Research & Applied
  • 10.3.2. Clinical
    • 10.3.2.1. Cardiovascular
    • 10.3.2.2. Oncology
    • 10.3.2.3. Genetic Diseases
    • 10.3.2.4. Reproductive Health
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. Academic & Research Institutes
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Illumina Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Thermo Fisher Scientific Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. QIAGEN
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. PacBio
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Oxford Nanopore Technologies
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Perkin Elmer, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. BGI
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)